4 results
Primary: To allow continued use of panobinostat to patients receiving single agent therapy with panobinostat in a Novartis-sponsored study.Secondary: To collect long term data on SAEs.
Primary* To compare the disease free survival (DFS) in patients with HL after achieving a complete response following AHSCT with HDT who are treated with panobinostat versus those who receive placebo based on investigator*s review of radiological…
To identify nasal microbial communities associated with Staphylococcus aureus carriage and study the influence over time of S. aureus-targeted decolonization treatment on these microbial communities
Compare the clinical efficacy of Epcoritamab to SOC (R-GemOx or BR)